Individualized Blood Glucose Control in ICU. The CONTROLING Study. A Double Blinded Multicentric Randomized Study. (CONTROLING)
Individualized Blood Glucose Control in ICU.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Belfort, France
- Hôpital Nord Franche Comté
-
Bourg-en-Bresse, France, 01012
- CH de BOURG-EN-BRESSE
-
Bourgoin Jallieu, France, 38302
- Centre Hospitalier de Bourgoin-Jallieu
-
Chartres, France
- CH Chartres
-
Clermont Ferrand, France, 63003
- CHU de Clermont Ferrand - Gabriel Montpied
-
Dijon, France, 21079
- CHU de Dijon - Complexe Hospitalier du Bocage
-
Montpellier, France, 34295
- CHU de Montpellier - Hôpital Lapeyronie
-
Nice, France, 06202
- CHU de Nice - Hôpital de l'Archet 1
-
Papeete, France
- CH de Polynésie Française
-
Pierre Benite, France, 69310
- Hospices Civils de Lyon - Centre Hospitalier Lyon Sud
-
Salon de Provence, France, 13658
- Centre Hospitalier de Salon de Provence
-
St Priest en Jarez, France, 42277
- CHU de Saint Etienne - Hopital Nord
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients are eligible for INCLUSION in the study if ALL the following criteria are met:
- Patient is 18 year old or older;
- At time of the patient's admission to the ICU the treating ICU specialist expects the patient will require treatment in the ICU that extends beyond the calendar day following the day of admission.
Exclusion Criteria:
Patients will be EXCLUDED from the study if ONE or MORE of the following criteria are present:
- Patient or legal surrogate decision maker does not accept the participation to the study;
- Imminent death (anticipated in less than 48 hours);
- The treating clinicians are not committed to full supportive care (no resuscitation, no renal replacement therapy limits in dose of vasoactive support);
- Patient is expected to be eating before the end of the day following admission;
- Admission in ICU for hypoglycemic encephalopathy or patient at risk for hypoglycaemia ( e.g. known insulin secreting tumour or history of unexplained or recurrent hypoglycaemia or fulminant hepatic failure);
- If a patient has previously been enrolled in the CONTROLING Study (patients cannot be enrolled in the CONTROLING Study more than once).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Individualized blood glucose target
Maintain blood glucose in individualized target based on glycated hemoglobin level (A1c); Blood glucose level is maintained bellow 1.59 × A1c - 1.59 (mmol/l).
|
On ICU admission, the glycated hemoglobin level (A1c) is measured and insulin IV is possibly administered using a web based nurse driven insulin infusion protocol (https://extranet.chu-lyon.fr/cpg)
to maintain blood glucose level below 10 mmol/l.
Glycated hemoglobin result triggers patient randomization.
Thereafter, during ICU stay, blood glucose level is maintained either below 1.59 × A1c - 1.59 (mmol/l) (Individualized blood glucose target group), or bellow 10 mmol/l (Conventional blood glucose target group).
|
|
Active Comparator: Conventional blood glucose target
Maintain blood glucose bellow 10 mmol/l.
|
On ICU admission, the glycated hemoglobin level (A1c) is measured and insulin IV is possibly administered using a web based nurse driven insulin infusion protocol (https://extranet.chu-lyon.fr/cpg)
to maintain blood glucose level below 10 mmol/l.
Glycated hemoglobin result triggers patient randomization.
Thereafter, during ICU stay, blood glucose level is maintained either below 1.59 × A1c - 1.59 (mmol/l) (Individualized blood glucose target group), or bellow 10 mmol/l (Conventional blood glucose target group).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
All-cause mortality
Time Frame: 90 days after randomization
|
90 days after randomization
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
All-cause mortality
Time Frame: 28 days after randomization and at ICU discharge
|
28 days after randomization and at ICU discharge
|
|
Length of intensive care unit stay
Time Frame: 90 days
|
90 days
|
|
Need for respiratory support, vasopressor support, dialysis and non-prophylactic antibiotics
Time Frame: during ICU stay (on average 10 days)
|
during ICU stay (on average 10 days)
|
|
incidence and severity of severe hypoglycemia (less than 2.2 mmol/l)
Time Frame: during ICU stay (on average 10 days)
|
during ICU stay (on average 10 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Julien BOHE, MD PhD, Hospices Civils de Lyon - Centre Hospitalier Lyon Sud
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2013.808
- 2013-A00806-39 (Other Identifier: ANSM)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.